Archemix Corporation

Other

Iveric Bio, Inc.

Datavine Research Services

Jeff C. Kurz

David Epstein

Charles Wilson

Thomas Greene McCauley

Markus Kurz

James Rottman

Jeffrey C Kurz

Claude Benedict

Dilara McCauley

John Louis Diener

Dilara Grate

Thomas Green Mccauley

Martin Stanton

Kristin Thompson

Anna J Zoltoski

Martin Betz

Thomas Mccauley

Anthony Dominic Keefe

Sara Chesworth Keene

Jeff C Kurz

Dilârâ McCauley

Nobuko Hamaguchi

Tony Keefe

Kristin A Marshall

Errol Desouza

Jeffrey Kurz

Sharyn O'Halloran

John Deiner

Jeffrey Preiss

Shannon Pendergrast

A user computing entity provides a specimen score for use in selecting a sperm for use in a fertilization event. The user computing entity provides the score by obtaining specimen image data comprising imaging data of one or more specimen, the imaging data corresponds to at least one type of imaging; generating a specimen scoring request including the specimen image data; providing the specimen scoring request for receipt by a network computing entity; receiving a specimen response comprising a respective specimen score for the one or more specimen, the respective specimen score for the one or more specimen generated by a machine-learning trained specimen analysis model; processing the respective specimen score for the one or more specimen to generate a graphical representation of the respective specimen score; and causing display of the graphical representation of the respective specimen score.

Machine learning characterization of sperm quality for sperm selection for assisted reproduction technology

The invention provides nucleic acid therapeutics and methods for using these nucleic acid therapeutics in the treatment of complement-related disorders.

Aptamer therapeutics useful in the treatment of complement-related disorders

Materials and methods are provided for producing and using aptamers useful as oncology therapeutics capable of binding to PDGF, PDGF isoforms, PDGF receptor, VEGF, and VEGF receptor or any combination thereof with great affinity and specificity. The compositions of the present invention are particularly useful in solid tumor therapy and can be used alone or in combination with known cytotoxic agents for the treatment of solid tumors. Also disclosed are aptamers having one or more CpG motifs embedded therein or appended thereto.

Aptamers comprising CPG motifs

Methods are provided for identifying aptamer regulators. Aptamer regulators are aptamers that bind to a target wherein binding of the aptamer regulator to the target increases the binding affinity of the target for a target partner relative to the affinity of the target for the target partner when the target is not bound by the aptamer regulator such that binding of the aptamer regulator to the target is a prerequisite for target-target partner complex formation.

Methods for identifying aptamer regulators

A computer-based method represents a subset of a dataset table of rows and columns. The method includes selecting a set of blocking variables corresponding to blocking columns of the dataset table. For each row in the dataset table, a tuple of values for the blocking columns uniquely identifies the row within the dataset table. The method also includes selecting a set of non-blocking variables that correspond to columns of the subset. The set of non-blocking variables does not intersect the set of blocking variables. The method also includes creating a block information structure that includes both the set of non-blocking variables and, for each blocking variable in the set of blocking variables, a set of values.

Method and apparatus for access, integration, and analysis of heterogeneous data sources via the manipulation of metadata objects

Materials and methods of use thereof are presented for the treatment of diabetes and other diseases. Therapeutic compositions including regulated aptamer therapeutic compositions with specificity to components of diabetes disease are presented with methods of administering these therapeutic compositions.

Regulated aptamer therapeutics

Methods for engineering a nucleic acid sensor molecule are provided. Biosensors comprise a plurality of nucleic acid sensor molecules labeled with a first signaling moiety and a second signaling moiety. The nucleic acid sensor molecules recognizes target molecules which do not naturally bind to DNA. Binding of a target molecule to the sensor molecules triggers a change in the proximity of the signaling moieties which leads to a change in the optical properties of the nucleic acid sensor molecules on the biosensor. Reagents and systems for performing the method are also provided. The method is useful in diagnostic applications and drug optimization.

Nucleic acid sensor molecules and methods of using same

Growing community of inventors

Huntington, NY, United States of America

David Epstein